MARKET

CELG

Celgene
CELG
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
19.84
4.606
6.37
77,001,936,000.00
Bristol-Myers Targeted by Senior Democrat on Offshore Tax Deal
Bloomberg · 4d ago
'Bloomberg Daybreak: Middle East' Full Show (01/12/2022)
Bloomberg · 01/12 09:14
Bristol Myers Is Very Focused on M&A, CEO Says
Bloomberg · 01/12 00:05
Catching up with a Bristol Myers Deal Hunter as the Virtual JPMorgan Conference Kicks Off 
Bloomberg · 01/10 18:07
Bristol-Myers Signs Cancer Deal With German Biotech Immatics
Bloomberg · 12/14/2021 13:02
Aurinia Extends Gain on Report of Bristol-Myers Approach
Bloomberg · 10/25/2021 13:55
Bristol Myers CEO on second quarter, infrastructure
Bloomberg · 07/28/2021 17:30
Bristol-Myers CEO on Delta Variant, Return of Office Workforce
Bloomberg · 07/28/2021 17:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CELG. Analyze the recent business situations of Celgene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CELG stock price target is 104.00 with a high estimate of 116.00 and a low estimate of 86.00.
High116.00
Average104.00
Low86.00
Current 108.24
EPS
Actual
Estimate
0.751.502.242.99
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Institutional Holdings
Institutions: 1.39K
Institutional Holdings: 536.66M
% Owned: 75.44%
Shares Outstanding: 711.40M
TypeInstitutionsShares
Increased
328
54.08M
New
74
2.28M
Decreased
607
50.75M
Sold Out
163
22.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Chief Executive Officer/Director
Mark Alles
Chief Financial Officer/Executive Vice President
David Elkins
Corporate Executive
Nadim Ahmed
Corporate Executive
Terrie Curran
Corporate Executive
Alise Reicin
Corporate Executive
Rupert Vessey
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President
Peter Kellogg
Lead Director
Michael Casey
Director
Hans Bishop
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
Independent Director
Carrie Cox
Independent Director
Michael Friedman
Independent Director
Julia Haller
Independent Director
Patricia Hemingway Hall
Independent Director
James Loughlin
Independent Director
Ernest Mario
Independent Director
John Weiland
No Data
  • All
  • Financials
  • Insiders
More

Webull offers kinds of Celgene stock information, including NASDAQ:CELG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELG stock methods without spending real money on the virtual paper trading platform.